SMO and prostate cancer: In support of this notion, Nanta et al. found that the SMO inhibitor, sonidegib, suppressed the epithelial-to-mesenchymal transition of the putative prostate cancer stem-cell phenotype CD133+/CD44+ cells and reduced their sphere-forming ability, while increasing apoptosis [25].